Samsung Bioepis Reports the Availability of Brenzys (biosimilar, etanercept) in Brazil

 Samsung Bioepis Reports the Availability of Brenzys (biosimilar, etanercept) in Brazil

Samsung Bioepis, Reports, Availability, Brenzys, biosimilar, etanercept, Brazil

Shots:

  • Samsung Bioepis reports the expansion of its global business with the entry of its first product, Brenzys (etanercept) in Brazil through Brazil’s public health system, Sistema Único de Saúde (SUS)
  • Samsung Bioepis signed a PDP agreement with Bionovis and Bio-Manguinhos/Fiocruz supplying Brenzis for the sales to SUS for a period of 10 years and will transfer its technology to the 2 companies enabling the manufacturing of Brenzys in Brazil 
  • Brenzys is a biosimilar of a reference product, Enbrel and has received ANVISA’s approval for RA, PsA, axSpA, AS and plaque Psoriasis in Dec’2017. Samsung Bioepis is expanding its business globally including China and collaborated with 3SBio & C-Bridge Capital to develop and commercialize its biosimilar candidates 

Click here to­ read full press release/ article | Ref: Samsung Bioepis | Image: BioPlus

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post